Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Trifluridine
Drug ID BADD_D02283
Description Trifluridine is a fluorinated pyrimidine nucleoside that is structurally related to [idoxuridine] [A35271]. It is an active antiviral agent in ophthalmic solutions used mainly in the treatment of primary keratoconjunctivitis and recurrent epithelial keratitis due to herpes simplex virus. It displays effective antiviral activity against Herpes simplex virus type 1 and 2 [A35271]. The combination product of trifluridine with tipiracil marketed as Lonsurf has been approved in Japan, the United States, and the European Union for the treatment of adult patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy. In the anticancer therapy, trifluridine acts as a thymidine-based nucleoside metabolic inhibitor that gets incorporated into DNA of cancer cells following cell uptake to aberrate DNA function during cell replication [F649].
Indications and Usage Trifluridine is used for the treatment of primay keratoconjunctivitis and recurrent epithelial keratitis due to herpes simplex virus, types 1 and 2 in ophthalmic solutions. Trifluridine, in combination with tipiracil as oral tablets, is indicated for the treatment of adult patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy [FDA Label].
Marketing Status approved; investigational
ATC Code S01AD02
DrugBank ID DB00432
KEGG ID D00391
MeSH ID D014271
PubChem ID 6256
TTD Drug ID D05RHI
NDC Product Code 59651-388; 76055-0037; 61314-044; 12785-0004; 70225-1108; 54893-0086; 68554-0118
UNII RMW9V5RW38
Synonyms Trifluridine | Trifluorothymidine | 2'-deoxy-5-(trifluoromethyl)uridine | Trifluoridine | 5-Trifluoromethyl-2'-deoxyuridine | 5 Trifluoromethyl 2' deoxyuridine | Triflumann | Virophta | Viroptic | TFT Ophtiole | Viromidin
Chemical Information
Molecular Formula C10H11F3N2O5
CAS Registry Number 70-00-8
SMILES C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Burning sensation17.02.06.001; 08.01.09.029--Not Available
Corneal oedema06.04.02.001--Not Available
Dry eye06.08.02.001--
Eyelid oedema23.04.01.003; 10.01.05.001; 06.04.04.004--Not Available
Hyperaemia24.03.02.002--Not Available
Hypersensitivity10.01.03.003--
Intraocular pressure increased13.07.04.002--Not Available
Keratopathy06.06.03.007--Not Available
Nausea07.01.07.001--
Pain08.01.08.004--
Punctate keratitis06.04.02.003--Not Available
Skin irritation23.03.04.009--Not Available
Vision blurred17.17.01.010; 06.02.06.007--
The 1th Page    1    Total 1 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene